HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Matthew Cardinal Selected Research

PF-05230907

1/2021Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Matthew Cardinal Research Topics

Disease

3Ulcer
01/2015 - 05/2009
3Diabetic Foot
01/2015 - 05/2009
3Wounds and Injuries (Trauma)
05/2009 - 01/2008
2Leg Ulcer
04/2013 - 05/2009
1Cerebral Hemorrhage
01/2021
1Infections
01/2015
1Surgical Wound
05/2009

Drug/Important Bio-Agent (IBA)

1PF-05230907IBA
01/2021
1Acetates (Acetic Acid Esters)FDA Link
03/2009
1Biomarkers (Surrogate Marker)IBA
01/2008

Therapy/Procedure

2Debridement
07/2011 - 05/2009
1Surgical Amputation (Amputations)
01/2015
1Therapeutics
04/2013
1Investigational Therapies (Experimental Therapy)
07/2011